Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 238

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 238
---
 our issued Ordinary Shares,
and accordingly, the Relationship Agreement terminated in accordance with its terms.

Deed of Indemnity

We have entered into a Deed
of Indemnity for the benefit of our Board of Directors and Company Secretary. For more information, see “Management—Compensation of Non-Executive Directors—Deed of Indemnity.”

Agreements with Directors and Senior Management

We have previously entered
into certain agreements with directors and our senior management related to their service on our Board of Directors or employment with
the Company. For more information, see “Management.”

| 118 |

<div align='center'>PRINCIPAL SHAREHOLDERS</div>

The following table sets forth information, to
our knowledge, as of December 31, 2024, regarding the beneficial ownership of Ordinary Shares, including:

| · | each person that is known by us to be a beneficial owner of 5% or more of Ordinary Shares (based on information 
 in our share register and information provided by such persons);                                                |

| · | each member of our Board of Directors; |

| · | each member of our senior management; and |

| · | all members of our Board of Directors and our senior management, taken as a group. |

Beneficial ownership of shares
is determined under rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment
power. Except as noted by footnote, and subject to community property laws where applicable, we believe, based upon the information provided
to us, that the persons and entities named in the table below have sole voting and investment power with respect to all Ordinary Shares
shown as beneficially owned by them. The percentage of beneficial ownership is based upon 6,685,918,922 Ordinary Shares outstanding as
of December 31, 2024. Ordinary Shares subject to options or warrants currently exercisable or exercisable within 60 days of December 31,
2024 are deemed to be outstanding and beneficially owned by the person holding the options for the purposes of computing the percentage
of beneficial ownership of that person and any group of which that person is a member, but are not deemed outstanding for the purpose
of computing the percentage of beneficial ownership for any other person. Unless otherwise indicated, the address for each holder listed
below is Biodexa Pharmaceuticals PLC, Caspian Point, 1 Caspian Way, Cardiff, CF10 4DQ, United Kingdom. All holders of